Francesco Restuccia

4PUBLICATIONS
51CO-AUTHORS
Regenerative medicine (incl. stem cells)Cancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Feb 13, 2025
Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS.

Angela Consagra, Luca Lanino, Najla H Al Ali

|Feb 04, 2025
CD19.CAR T-cell-derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy.

Paola Lanuti, Francesco Guardalupi, Giulia Corradi

|Jul 14, 2023
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience.

Luana Fianchi, Fabio Guolo, Francesco Marchesi

|May 24, 2023
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.

Luca Lanino, Francesco Restuccia, Alessandra Perego

Pageof 1

Frequent Collaborators

2 joint publications

Valeria Santini

1 joint publications

Luca Lanino

1 joint publications

Daniela Cilloni

1 joint publications

Antonella Poloni